NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 9th April 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items

2. Dr James Fotheringham (Vice-chair) Items 5.1 to 5.2.1

3. Alan Thomas Present for all items

4. Dominic Pivonka Present for all items

5. Dr Craig Buckley Items 5.1 to 5.2.1

6 .Dr Ian Bernstein Present for all items

7. Dr Justin Daniels Present for all items

8. Dr Mohit Sharma Present for all items

9. Dr Patrick De Barr Present for all items

11. Hugo Pedder Present for all items

12. Jaqueline Tomlinson Present for all items

13. Mario Ganau Items 5.1 to 5.2.1

14. Professor G.J. Melendez-Torres Items 1.1 to 4.2.2

15. Richard Ballerand Present for all items

NICE staff (key players) present

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Mary Hughes, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Giacomo De Guisa, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Sally Doss, Heath Technology Assessment Adviser Items 5.1 to 5.2.1

Albany Chandler, Heath Technology Assessment Analyst Items 5.1 to 5.2.1

External assessment group representatives present

Maiwenn Al, Kleijnen Systematic Reviews Ltd Items 1.1 to 4.1.3

Huiqin Yang, Kleijnen Systematic Reviews Ltd Items 1.1 to 4.1.3

Ewen Cummins, Warwick Evidence Items 5.1 to 5.1.3

Lena Alkhudairy, Warwick Evidence  Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Peter Clark, NHSE CDF clinical lead Items 1.1 to 4.2.2

Sanjeev Patel, NHSE clinical adviser (non-oncology) Items 5.1 to 5.2.2

Sarah Le Brocq, Director and Patient Advocate Patient expert, nominated by All About Obesity Items 5.1 to 5.1.3

Dr Dimitris Papamargaritis, Associate Professor and Honorary Consultant in Diabetes and Endocrinology, Clinical expert, nominated by the Association for the Study of Obesity

Items 5.1 to 5.1.3

Matthew Capehorn. Clinical expert, nominated by Lilly Items 5.1 to 5.1.3

Paula Wilkinson, commissioning expert Items 5.1 to 5.1.3

Observers present

Milena Wobbe, Technical analyst, managed access Items 1.1 to 4.2.2

Sarah Wilkes, Technical adviser, commercial Items 1.1 to 4.2.2

Oyewumi Afolabi, Technical analyst, commercial Items 1.1 to 4.2.2

Stephen Norton, Technical analyst, managed access Items 5.1 to 5.2.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Radha Todd, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Min Ven Teo, Pratheeban Nambyiah, Ana Duarte, Andrew Champion, Fiona MacPherson Smith, Peter Baker-Gulliver, Becky Pennington and Mohamad Farhat.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 12th March 2024.

### Appraisal of [Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11039)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp and Dohme
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10832).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Radha Todd.
  2. Part 2 –Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10832>.

### Appraisal of [Tirzepatide for managing overweight and obesity [ID6179]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11156)

5.1 Part 1 – Open session

5.1.1 The chair, James Fotheringham welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly & Company.

5.1.2 The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11156).

5.1.3 The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by James Fortheringham.

5.2 Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)

5.2.1 The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.

5.2.2 The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11156>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 14th May and will start promptly at 9am.